@article{3061406, title = "Discovery of 6-[4-(6-nitroxyhexanoyl)piperazin-1-yl)]-9H-purine, as pharmacological post-conditioning agent", author = "Koufaki, M. and Fotopoulou, T. and Iliodromitis, E.K. and Bibli, S.-I. and Zoga, A. and Kremastinos, D.T. and Andreadou, I.", journal = "BIOORGANIC AND MEDICINAL CHEMISTRY", year = "2012", volume = "20", number = "19", pages = "5948-5956", issn = "0968-0896", doi = "10.1016/j.bmc.2012.07.037", keywords = "5' o nitroadenosine; 6 (4 nitroxyacetylpiperazin 1 yl) 9h purine; 6 [4 (1,2 dithiolan 3 pentanoyl)piperazin 1 yl] 9h purine; 6 [4 (6 nitroxyhexanoyl)piperazin 1 yl] 9h purine; 9 (5 o nitro 1beta dextro ribofuranosyl) 6 (piperidin 1 yl) 9h purine; cardiovascular agent; n (2 nitroxyethyl) 2 (9h purin 6 ylamin)acetamide; n (2 nitroxyethyl) 6 (piperidin 1 yl) 9h purine acetamide; n (2 nitroxyethyl) 6 (piperidine 1 yl) purine 8 carboxamide; purine derivative; unclassified drug, animal experiment; animal model; animal tissue; article; controlled study; drug structure; drug synthesis; heart infarction; heart infarction size; heart muscle ischemia; ischemic postconditioning; ischemic preconditioning; male; nonhuman; reperfusion injury; treatment response, Animals; Cardiotonic Agents; Heart; Hemodynamics; Ischemic Postconditioning; Myocardial Infarction; Myocardium; Nitrates; Purines; Rabbits, Oryctolagus cuniculus", abstract = "Novel purine analogues bearing nitrate esters were designed and synthesized in an effort to develop compounds triggering endogenous cardioprotective mechanisms such as ischemic preconditioning (IPC) or postconditioning (PostC). The majority of the compounds reduced infarct size compared to the control group in anesthetized rabbits, whereas administration of the most active analogue 16 at a dose of 3.8 μmol/kg resulted on a significant reduction of infarct size, compared to PostC group (13.4 ± 1.9% vs 26.4 ± 2.3%). These findings introduce a novel class of promising pharmacological compounds that could be used as mimics or enhancers of PostC. © 2012 Elsevier Ltd. All rights reserved." }